Elderly Female of Type 2 Diabetes (T2D) and Dementia with Clinical Improvement by Imeglimin (Twymeeg)

Asploro journal of biomedical and clinical case reports Pub Date : 2023-02-04 DOI:10.36502/2023/asjbccr.6284

M. Okada, H. Bando, Noboru Iwatsuki, K. Sakamoto, T. Ogawa

引用次数: 5

Abstract

Background: Recent diabetic focus includes imeglimin (Twymeeg). Case Presentation: The case was an 83-year-old female with 19 years of type 2 diabetes (T2D) associated with recent treatment for dementia. Result: HbA1c decreased from 10.0% to 6.6% for 4 months by Twymeeg 2000 mg/day. For neuropsychiatric symptoms in dementia, memantine and tiapride were provided and controlled. Furthermore, zinc acetate hydrate (Novelzin) was continued for T2D and dementia. Discussion and Conclusion: Twymeeg administration was effective as the results of Trials of IMeglimin for Efficacy and Safety (TIMES) 2 and 3. Perspectives on the efficacy of zinc were discussed including Alzheimer’s-Plus with low zinc (APLZ).

查看原文本刊更多论文

Imeglimin（Twymeeg）改善老年女性2型糖尿病（T2D）和痴呆症的临床疗效

背景：最近的糖尿病焦点包括依格列明（Twymeeg）。病例介绍：该病例是一名83岁的女性，患有19年的2型糖尿病（T2D），与最近的痴呆症治疗有关。结果：Twymeeg 2000mg/天治疗4个月，HbA1c由10.0%降至6.6%。对于痴呆症的神经精神症状，提供并控制了美金刚和硫必利。此外，醋酸锌水合物（Novelzin）继续用于T2D和痴呆症。讨论和结论：根据依格列明疗效和安全性试验（TIMES）2和3的结果，Twymeeg给药是有效的。讨论了锌疗效的前景，包括低锌阿尔茨海默氏症（APLZ）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asploro journal of biomedical and clinical case reports

自引率

0.00%

发文量